Pancreatic cancer remains one of the most complex and challenging cancers. The five-year survival rate is only five percent, and the disease is not that rare: more than 30,000 cases will be diagnosed this year. Nabeel and his collaborators throughout DF/HCC are tackling this challenge by sequentially decoding the genetic program that goes awry in pancreatic cancer. This cross-disciplinary, groundbreaking work allows them to understand how the disease develops and progresses with the hope of finding targeted treatments for patients with this difficult disease.
You are using an unsupported browser. Please use the latest version of
Chrome, Firefox, Safari or Edge.